Compare SSBI & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSBI | TLPH |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | 103 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.1M | 70.3M |
| IPO Year | N/A | 2010 |
| Metric | SSBI | TLPH |
|---|---|---|
| Price | $12.66 | $1.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.2K | ★ 289.0K |
| Earning Date | 04-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.35 | $0.69 |
| 52 Week High | $14.00 | $1.57 |
| Indicator | SSBI | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.03 | 44.98 |
| Support Level | $12.39 | $1.17 |
| Resistance Level | $13.86 | $1.29 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 1.87 | 27.27 |
Summit State Bank provides various banking products and services to individuals and businesses in Sonoma County, California. It offers personal and business checking, money market, sweep, savings, and demand accounts; time certificates of deposit; and specialized deposit accounts, such as professional, small business packaged, tiered, and retirement plan accounts. The company also provides loans, including commercial loans and leases; lines of credit; commercial real estate, small business administration, residential mortgage, and construction loans; home equity lines of credit; and term and equipment loans, as well as loans to agriculture-related businesses.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.